Genentech, Inc.
NEWS
Patients who received Tecentriq and Avastin in addition to standard chemo showed a 38 percent reduction in the risk of the disease getting worse or death.
Genentech’s Hemlibra just got approved but is expected to bring in around $2 billion in peak sales.
A look at the FDA’s long-awaited guidelines on how it will regulate regenerative medicine products, including stem cells.
Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents.
Genentech announced that its Phase III HAVEN 3 study of Hemlibra in adults and adolescents with hemophilia A without inhibitors to factor VIII had positive results.
Genentech scored two approvals from the FDA this week.
The drug will be used to prevent or reduce the frequency of bleeding episodes in certain patients.
Arvinas expanded an ongoing licensing deal with Genentech.
Denali plans to make a $100M IPO under the symbol DNLI.
JOBS
IN THE PRESS